Cycloserine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Cycloserine
| |
| Systematic (IUPAC) name | |
| 4-aminoisoxazolidin-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | J04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C3H6N2O2 |
| Mol. mass | 102.092 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Cycloserine | |
|
Articles | |
|---|---|
|
Most recent articles on Cycloserine Most cited articles on Cycloserine | |
|
Media | |
|
Powerpoint slides on Cycloserine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Cycloserine at Clinical Trials.gov Clinical Trials on Cycloserine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Cycloserine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Cycloserine Discussion groups on Cycloserine Patient Handouts on Cycloserine Directions to Hospitals Treating Cycloserine Risk calculators and risk factors for Cycloserine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Cycloserine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Cycloserine is an oral broad spectrum antibiotic effective against tuberculosis, by inhibiting cell wall synthesis of TB bacilli at early stage of peptidoglycan synthesis. For the treatment against tuberculosis, it is classified as a second line drug.
It is also being trialed for treatment of phobias as well as an adjuvant to conventional treatments for depression, obsessive-compulsive disorder and schizophrenia.
The side effects are mainly CNS manifestations i.e. headache, irritability, depression, convulsions. Co-administration of pyridoxine can reduce the incidence of some of the CNS side effects(e.g. convulsions).
These psychotropic responses are related to D-cycloserine's action as a partial agonist of the neuronal NMDA receptor for glutamate and have been examined in implications with sensory-related fear extinction in the amygdala. See Michael Davis, Barbara Rothbaum, Kerry Ressler et al. and their work with PTSD at Emory University's School of Medicine. [1]
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
